On Monday, Shares of Boston Scientific Corporation (NYSE:BSX), lost -0.27% to $18.28.
Boston Scientific (BSX) has received United States (U.S.) Food and Drug Administration (FDA) approval and CE Mark for the AngioJet™ ZelanteDVT™ thrombectomy catheter to treat deep vein thrombosis (DVT) in large-diameter upper and lower limb peripheral veins.
The ZelanteDVT catheter is the first AngioJet catheter designed specifically to treat DVT, a challenging condition that may affect up to 2.5 million people in the U.S. and Europe annually, with a majority of cases occurring during or soon after a hospitalization1, 2. Offering four times the thrombus removal power of current market-leading AngioJet catheters, the ZelanteDVT catheter was designed to efficiently remove large venous clot burdens and facilitate rapid restoration of blood flow, potentially decreasing procedural time, quickly relieving symptoms and reducing late complications.
“There has been a clinical need for a stronger thrombectomy catheter to support treatment modalities in addressing challenging cases of deep vein thrombosis,” said Mitchell Silver, DO, FACC, Riverside Hospital in Columbus, Ohio. “The unique features of the ZelanteDVT catheter make it well-suited to treat a wide range of thrombotic occlusions thus potentially decreasing bleeding risks and reducing patients’ need for intensive care stays.”
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in three segments: Cardiovascular, Rhythm Administration, and Med Surg. It offers interventional cardiology products, counting coronary stent systems used in the treatment of coronary artery disease; coronary technology products to treat atherosclerosis; intraluminal catheter-directed ultrasound imaging catheters and systems for use in coronary arteries and heart chambers, in addition to peripheral vessels; and structural heart therapy systems.
Shares of Brocade Communications Systems, Inc. (NASDAQ:BRCD), declined -0.16% to $9.39, during its last trading session.
Brocade, declared that it will take part in forthcoming investor financial conferences.
- Credit Suisse 19th Annual Technology, Media & Telecom Conference
Tuesday, December 1, 2015
4:30 p.m. to 5:00 p.m. MST
The Phoenician, Scottsdale, Arizona
Lloyd Carney, Chief Executive Officer
- Barclays Global Technology, Media and Telecommunications Conference
Tuesday, December 8, 2015
1:40 p.m. to 2:10 p.m. PT
The Palace Hotel, San Francisco, California
Kelly Herrell, SVP & General Manager, Software Networking
Brocade Communications Systems, Inc. provides storage area networking (SAN) and Internet protocol networking solutions for businesses and organizations worldwide. It operates through SAN Products, IP Networking Products, and Global Services segments. The SAN Products segment offers infrastructure products and solutions, such as fiber channel SAN backbones, directors, fabrics, and embedded switches that assist customers in the development and delivery of storage and server consolidation, disaster recovery and data security, and compliance issues regarding data administration; and fabric extension, switching, and routing solutions.
Finally, Shares of Hovnanian Enterprises, Inc. (NYSE:HOV), ended its last trade with 1.67% gain, and closed at $1.83.
Moments ago, Trader’s Choice released new research updates concerning several important developing situations counting the following equities: Home Trust Bancshares Inc (HTBI), Liquidity Services Inc (LQDT), Galena Bio pharma Inc (GALE) and Hovnanian Enterprises Inc (HOV). Trader’s Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
Highlights from recently’s reports comprise:
On Monday, November 23, 2015, the NASDAQ Composite ended at 5,102.48, down 0.05%, the Dow Jones Industrial Average edged 0.17% lower, to finish the day at 17,792.68, and the S&P 500 closed at 2,086.59, down 0.12%.
Home Trust Bancshares Inc’s stock advanced 1.01% to close Monday’s session at USD 19.98. The share price vacillated between USD 19.81 and USD 20.00. The stock recorded a trading volume of 0.05 million shares, which was below its 50-day daily average volume of 0.08 million shares and below its 52-week average volume of 0.06 million shares. Over the last three days HomeTrust Bancshares Inc’s shares have advanced 2.78% and in the past one week it has moved up 3.42%. Moreover, in the last six months, the stock has gained 27.50% and year to date, the shares have picked up 19.93%. On a compounded total return basis, the company has returned 8.65% in the past three months, and 27.50% in the past one year. Further, the company is trading at a price to earnings ratio of 45.41. This compares to a historical PE ratio of 39.93.
- Liquidity Services Inc’s stock edged higher by 3.21% to close Monday’s session at USD 6.76. The company’s shares oscillated between USD 6.44 and USD 6.76. The stock recorded a trading volume of 0.78 million shares, which was above its 50-day daily average volume of 0.30 million shares and above its 150-day daily average volume of 0.28 million shares. Over the last three days, Liquidity Services Inc’s shares have declined by 14.21% and in the past one week it has moved down 16.85%. Furthermore, over the last three months, the stock has lost 5.85% and in the past six months, the shares have shed 35.74%. The stock is at a price to book ratio of 0.75. The historical PB ratio is near to 1.03. Additionally, the stock is trading at a price to cash flow ratio of 6.02 and price to sales ratio of 0.45. Liquidity Services Inc is having a market cap of USD 202.98 million.
- The stock of Galena Biopharma Inc gained 1.36% to close Monday’s session at USD 1.49 which was below its 200-day moving average of USD 1.65. The shares of the company moved in the range of USD 1.45 and USD 1.50. A trading volume of 0.84 million shares was recorded, which was lower than its 150-day daily average volume of 2.19 million shares and below its 52-week average volume of 2.21 million shares. Galena Biopharma Inc’s shares have a market cap of USD 241.24 million. Over the last five days, Galena Biopharma Inc’s shares have advanced 1.36% while in the past one month, it has lost 8.02%. Additionally, over the past six months, the shares have registered a profit of 9.56%. The company has returned 11.19% in the last three months, on a compounded total return basis. Further, Galena Biopharma Inc has an Enterprise Value of USD 208.88 million.
- Hovnanian Enterprises Inc’s stock raised by 1.22% to close Monday’s session at USD 1.66. The company’s shares fluctuated in the range of USD 1.65 and USD 1.70. A total of 1.43 million shares exchanged hands, which was lesser than its 50-day daily average volume of 2.14 million shares and was below its 52-week average volume of 2.38 million shares. Over the last three days Hovnanian Enterprises Inc’s shares have declined by 2.92% and in the past one week it has moved up 0.61%. Furthermore, over the last three months, the stock has gained 3.75% while in the past six months, the shares have shed 46.79%. Further, the company is trading at a price to earnings ratio of 0.99 contrast to a historical PE ratio of 2.01. Additionally, the stock is trading at a price to cash flow ratio of 13.59 and at a price to sales ratio of 0.10. Further, Hovnanian Enterprises Inc’s shares have a Relative Strength Index (RSI) of 36.34.
Hovnanian Enterprises, Inc. designs, constructs, markets, and sells residential homes in the United States. It constructs single-family detached homes, attached townhomes and condominiums, urban infill, and active adult homes.